Cardax, Inc.
Cardax, Inc. CDXI Peers
See (CDXI) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CDXI | $0.00 | +400.00% | 401 | N/A | -$0.65 | N/A |
| NONOF | $77.81 | -2.43% | 345.4B | 21.61 | $3.60 | +2.17% |
| CSLLY | $78.60 | +1.39% | 152.2B | 28.90 | $2.72 | +1.68% |
| CMXHF | $150.89 | +1.51% | 73.1B | 27.63 | $5.46 | +1.84% |
| UCBJF | $195.59 | -0.61% | 37.2B | 31.05 | $6.30 | +0.81% |
| UCBJY | $93.53 | -0.45% | 35.6B | 29.60 | $3.16 | +0.84% |
| ARGNF | $562.00 | -4.18% | 34.3B | 34.23 | $16.42 | N/A |
| BBIXF | $0.05 | +50900.00% | 34B | -5.10 | -$0.01 | N/A |
| ODTC | $22,005.00 | +29.44% | 24.1B | -0.08 | -$268,995.00 | N/A |
| IVBXF | $10.50 | +3.63% | 17.3B | -1050.00 | -$0.01 | N/A |
Stock Comparison
CDXI vs NONOF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, NONOF has a market cap of 345.4B. Regarding current trading prices, CDXI is priced at $0.00, while NONOF trades at $77.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas NONOF's P/E ratio is 21.61. In terms of profitability, CDXI's ROE is +0.00%, compared to NONOF's ROE of +0.81%. Regarding short-term risk, CDXI is more volatile compared to NONOF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CSLLY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CSLLY has a market cap of 152.2B. Regarding current trading prices, CDXI is priced at $0.00, while CSLLY trades at $78.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CSLLY's P/E ratio is 28.90. In terms of profitability, CDXI's ROE is +0.00%, compared to CSLLY's ROE of +0.26%. Regarding short-term risk, CDXI is more volatile compared to CSLLY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CMXHF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CMXHF has a market cap of 73.1B. Regarding current trading prices, CDXI is priced at $0.00, while CMXHF trades at $150.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CMXHF's P/E ratio is 27.63. In terms of profitability, CDXI's ROE is +0.00%, compared to CMXHF's ROE of +0.15%. Regarding short-term risk, CDXI is more volatile compared to CMXHF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs UCBJF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, UCBJF has a market cap of 37.2B. Regarding current trading prices, CDXI is priced at $0.00, while UCBJF trades at $195.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas UCBJF's P/E ratio is 31.05. In terms of profitability, CDXI's ROE is +0.00%, compared to UCBJF's ROE of +0.03%. Regarding short-term risk, CDXI is more volatile compared to UCBJF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs UCBJY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, UCBJY has a market cap of 35.6B. Regarding current trading prices, CDXI is priced at $0.00, while UCBJY trades at $93.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas UCBJY's P/E ratio is 29.60. In terms of profitability, CDXI's ROE is +0.00%, compared to UCBJY's ROE of +0.03%. Regarding short-term risk, CDXI is more volatile compared to UCBJY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ARGNF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ARGNF has a market cap of 34.3B. Regarding current trading prices, CDXI is priced at $0.00, while ARGNF trades at $562.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ARGNF's P/E ratio is 34.23. In terms of profitability, CDXI's ROE is +0.00%, compared to ARGNF's ROE of +0.16%. Regarding short-term risk, CDXI is more volatile compared to ARGNF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BBIXF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BBIXF has a market cap of 34B. Regarding current trading prices, CDXI is priced at $0.00, while BBIXF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BBIXF's P/E ratio is -5.10. In terms of profitability, CDXI's ROE is +0.00%, compared to BBIXF's ROE of -2.10%. Regarding short-term risk, CDXI is more volatile compared to BBIXF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ODTC Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ODTC has a market cap of 24.1B. Regarding current trading prices, CDXI is priced at $0.00, while ODTC trades at $22,005.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ODTC's P/E ratio is -0.08. In terms of profitability, CDXI's ROE is +0.00%, compared to ODTC's ROE of +0.07%. Regarding short-term risk, CDXI is more volatile compared to ODTC. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs IVBXF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, IVBXF has a market cap of 17.3B. Regarding current trading prices, CDXI is priced at $0.00, while IVBXF trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas IVBXF's P/E ratio is -1050.00. In terms of profitability, CDXI's ROE is +0.00%, compared to IVBXF's ROE of -0.01%. Regarding short-term risk, CDXI is more volatile compared to IVBXF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs WXXWY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, WXXWY has a market cap of 14.1B. Regarding current trading prices, CDXI is priced at $0.00, while WXXWY trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas WXXWY's P/E ratio is 30.41. In terms of profitability, CDXI's ROE is +0.00%, compared to WXXWY's ROE of +0.06%. Regarding short-term risk, CDXI is more volatile compared to WXXWY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs GNMSF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, GNMSF has a market cap of 13.7B. Regarding current trading prices, CDXI is priced at $0.00, while GNMSF trades at $222.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas GNMSF's P/E ratio is 13.05. In terms of profitability, CDXI's ROE is +0.00%, compared to GNMSF's ROE of +0.26%. Regarding short-term risk, CDXI is more volatile compared to GNMSF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs WXIBF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, WXIBF has a market cap of 13B. Regarding current trading prices, CDXI is priced at $0.00, while WXIBF trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas WXIBF's P/E ratio is 32.00. In terms of profitability, CDXI's ROE is +0.00%, compared to WXIBF's ROE of +0.06%. Regarding short-term risk, CDXI is more volatile compared to WXIBF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SBMFF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SBMFF has a market cap of 12B. Regarding current trading prices, CDXI is priced at $0.00, while SBMFF trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SBMFF's P/E ratio is 33.54. In terms of profitability, CDXI's ROE is +0.00%, compared to SBMFF's ROE of +0.11%. Regarding short-term risk, CDXI is more volatile compared to SBMFF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SBHMY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SBHMY has a market cap of 8.7B. Regarding current trading prices, CDXI is priced at $0.00, while SBHMY trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SBHMY's P/E ratio is 33.62. In terms of profitability, CDXI's ROE is +0.00%, compared to SBHMY's ROE of +0.11%. Regarding short-term risk, CDXI is more volatile compared to SBHMY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs TRSBF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, TRSBF has a market cap of 7.1B. Regarding current trading prices, CDXI is priced at $0.00, while TRSBF trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas TRSBF's P/E ratio is 25.00. In terms of profitability, CDXI's ROE is +0.00%, compared to TRSBF's ROE of +0.11%. Regarding short-term risk, CDXI is more volatile compared to TRSBF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs TLPPF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, TLPPF has a market cap of 5.5B. Regarding current trading prices, CDXI is priced at $0.00, while TLPPF trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas TLPPF's P/E ratio is 180.00. In terms of profitability, CDXI's ROE is +0.00%, compared to TLPPF's ROE of +0.14%. Regarding short-term risk, CDXI is more volatile compared to TLPPF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ABCZF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ABCZF has a market cap of 5.1B. Regarding current trading prices, CDXI is priced at $0.00, while ABCZF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ABCZF's P/E ratio is 2225.00. In terms of profitability, CDXI's ROE is +0.00%, compared to ABCZF's ROE of -0.01%. Regarding short-term risk, CDXI is more volatile compared to ABCZF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs INCPF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, INCPF has a market cap of 4.9B. Regarding current trading prices, CDXI is priced at $0.00, while INCPF trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas INCPF's P/E ratio is -108.67. In terms of profitability, CDXI's ROE is +0.00%, compared to INCPF's ROE of -0.05%. Regarding short-term risk, CDXI is more volatile compared to INCPF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs AKBLF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, AKBLF has a market cap of 4.8B. Regarding current trading prices, CDXI is priced at $0.00, while AKBLF trades at $21.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas AKBLF's P/E ratio is 33.36. In terms of profitability, CDXI's ROE is +0.00%, compared to AKBLF's ROE of +0.18%. Regarding short-term risk, CDXI is more volatile compared to AKBLF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs LABFF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, LABFF has a market cap of 4.6B. Regarding current trading prices, CDXI is priced at $0.00, while LABFF trades at $90.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas LABFF's P/E ratio is 28.95. In terms of profitability, CDXI's ROE is +0.00%, compared to LABFF's ROE of +0.39%. Regarding short-term risk, CDXI is more volatile compared to LABFF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ZLDPF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ZLDPF has a market cap of 4.5B. Regarding current trading prices, CDXI is priced at $0.00, while ZLDPF trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ZLDPF's P/E ratio is -24.07. In terms of profitability, CDXI's ROE is +0.00%, compared to ZLDPF's ROE of -0.13%. Regarding short-term risk, CDXI is more volatile compared to ZLDPF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs GNNSF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, GNNSF has a market cap of 4.4B. Regarding current trading prices, CDXI is priced at $0.00, while GNNSF trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas GNNSF's P/E ratio is -25.62. In terms of profitability, CDXI's ROE is +0.00%, compared to GNNSF's ROE of -0.06%. Regarding short-term risk, CDXI is more volatile compared to GNNSF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs REGMF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, REGMF has a market cap of 3.4B. Regarding current trading prices, CDXI is priced at $0.00, while REGMF trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas REGMF's P/E ratio is -13.32. In terms of profitability, CDXI's ROE is +0.00%, compared to REGMF's ROE of -0.48%. Regarding short-term risk, CDXI is more volatile compared to REGMF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CAMRF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CAMRF has a market cap of 3.3B. Regarding current trading prices, CDXI is priced at $0.00, while CAMRF trades at $56.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CAMRF's P/E ratio is 59.53. In terms of profitability, CDXI's ROE is +0.00%, compared to CAMRF's ROE of +0.14%. Regarding short-term risk, CDXI is more volatile compared to CAMRF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs GLPGF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, GLPGF has a market cap of 3.2B. Regarding current trading prices, CDXI is priced at $0.00, while GLPGF trades at $48.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas GLPGF's P/E ratio is -15.51. In terms of profitability, CDXI's ROE is +0.00%, compared to GLPGF's ROE of -0.06%. Regarding short-term risk, CDXI is more volatile compared to GLPGF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs TKBIF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, TKBIF has a market cap of 2.8B. Regarding current trading prices, CDXI is priced at $0.00, while TKBIF trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas TKBIF's P/E ratio is 18.71. In terms of profitability, CDXI's ROE is +0.00%, compared to TKBIF's ROE of N/A. Regarding short-term risk, CDXI is more volatile compared to TKBIF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs MPSYF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, MPSYF has a market cap of 2.8B. Regarding current trading prices, CDXI is priced at $0.00, while MPSYF trades at $73.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas MPSYF's P/E ratio is -12.13. In terms of profitability, CDXI's ROE is +0.00%, compared to MPSYF's ROE of +2.51%. Regarding short-term risk, CDXI is more volatile compared to MPSYF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ASPHF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ASPHF has a market cap of 2.2B. Regarding current trading prices, CDXI is priced at $0.00, while ASPHF trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ASPHF's P/E ratio is -35.83. In terms of profitability, CDXI's ROE is +0.00%, compared to ASPHF's ROE of -0.70%. Regarding short-term risk, CDXI is more volatile compared to ASPHF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BVNRY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BVNRY has a market cap of 2.2B. Regarding current trading prices, CDXI is priced at $0.00, while BVNRY trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BVNRY's P/E ratio is 10.77. In terms of profitability, CDXI's ROE is +0.00%, compared to BVNRY's ROE of +0.12%. Regarding short-term risk, CDXI is more volatile compared to BVNRY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BVNKF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BVNKF has a market cap of 2B. Regarding current trading prices, CDXI is priced at $0.00, while BVNKF trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BVNKF's P/E ratio is 10.12. In terms of profitability, CDXI's ROE is +0.00%, compared to BVNKF's ROE of +0.12%. Regarding short-term risk, CDXI is more volatile compared to BVNKF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SYGGF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SYGGF has a market cap of 2B. Regarding current trading prices, CDXI is priced at $0.00, while SYGGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SYGGF's P/E ratio is -0.47. In terms of profitability, CDXI's ROE is +0.00%, compared to SYGGF's ROE of -0.62%. Regarding short-term risk, CDXI is more volatile compared to SYGGF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BTTAY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BTTAY has a market cap of 1.9B. Regarding current trading prices, CDXI is priced at $0.00, while BTTAY trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BTTAY's P/E ratio is -67.31. In terms of profitability, CDXI's ROE is +0.00%, compared to BTTAY's ROE of +0.05%. Regarding short-term risk, CDXI is more volatile compared to BTTAY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs MEOBF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, MEOBF has a market cap of 1.9B. Regarding current trading prices, CDXI is priced at $0.00, while MEOBF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas MEOBF's P/E ratio is -16.67. In terms of profitability, CDXI's ROE is +0.00%, compared to MEOBF's ROE of -0.15%. Regarding short-term risk, CDXI is more volatile compared to MEOBF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BRCTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BRCTF has a market cap of 1.9B. Regarding current trading prices, CDXI is priced at $0.00, while BRCTF trades at $20.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BRCTF's P/E ratio is 19.72. In terms of profitability, CDXI's ROE is +0.00%, compared to BRCTF's ROE of -0.19%. Regarding short-term risk, CDXI is more volatile compared to BRCTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SHJBF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SHJBF has a market cap of 1.8B. Regarding current trading prices, CDXI is priced at $0.00, while SHJBF trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SHJBF's P/E ratio is -7.22. In terms of profitability, CDXI's ROE is +0.00%, compared to SHJBF's ROE of -0.27%. Regarding short-term risk, CDXI is more volatile compared to SHJBF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs GENSF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, GENSF has a market cap of 1.7B. Regarding current trading prices, CDXI is priced at $0.00, while GENSF trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas GENSF's P/E ratio is -289.00. In terms of profitability, CDXI's ROE is +0.00%, compared to GENSF's ROE of +0.01%. Regarding short-term risk, CDXI is more volatile compared to GENSF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PHMMF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PHMMF has a market cap of 1.7B. Regarding current trading prices, CDXI is priced at $0.00, while PHMMF trades at $96.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PHMMF's P/E ratio is 74.00. In terms of profitability, CDXI's ROE is +0.00%, compared to PHMMF's ROE of +0.10%. Regarding short-term risk, CDXI is more volatile compared to PHMMF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BIESF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BIESF has a market cap of 1.6B. Regarding current trading prices, CDXI is priced at $0.00, while BIESF trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BIESF's P/E ratio is -44.44. In terms of profitability, CDXI's ROE is +0.00%, compared to BIESF's ROE of +0.05%. Regarding short-term risk, CDXI is more volatile compared to BIESF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ONTTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ONTTF has a market cap of 1.6B. Regarding current trading prices, CDXI is priced at $0.00, while ONTTF trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ONTTF's P/E ratio is -7.50. In terms of profitability, CDXI's ROE is +0.00%, compared to ONTTF's ROE of -0.27%. Regarding short-term risk, CDXI is more volatile compared to ONTTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PPTDF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PPTDF has a market cap of 1.4B. Regarding current trading prices, CDXI is priced at $0.00, while PPTDF trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PPTDF's P/E ratio is 14.05. In terms of profitability, CDXI's ROE is +0.00%, compared to PPTDF's ROE of +0.26%. Regarding short-term risk, CDXI is more volatile compared to PPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CSBTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CSBTF has a market cap of 1.3B. Regarding current trading prices, CDXI is priced at $0.00, while CSBTF trades at $32.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CSBTF's P/E ratio is -232.93. In terms of profitability, CDXI's ROE is +0.00%, compared to CSBTF's ROE of -0.15%. Regarding short-term risk, CDXI is more volatile compared to CSBTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs NURPF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, NURPF has a market cap of 1.1B. Regarding current trading prices, CDXI is priced at $0.00, while NURPF trades at $8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas NURPF's P/E ratio is 12.41. In terms of profitability, CDXI's ROE is +0.00%, compared to NURPF's ROE of +0.49%. Regarding short-term risk, CDXI is more volatile compared to NURPF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SNBIF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SNBIF has a market cap of 1B. Regarding current trading prices, CDXI is priced at $0.00, while SNBIF trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SNBIF's P/E ratio is -22.59. In terms of profitability, CDXI's ROE is +0.00%, compared to SNBIF's ROE of -0.92%. Regarding short-term risk, CDXI is more volatile compared to SNBIF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ASCLF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ASCLF has a market cap of 900.1M. Regarding current trading prices, CDXI is priced at $0.00, while ASCLF trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ASCLF's P/E ratio is -23.21. In terms of profitability, CDXI's ROE is +0.00%, compared to ASCLF's ROE of -0.09%. Regarding short-term risk, CDXI is more volatile compared to ASCLF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PHGUF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PHGUF has a market cap of 758.1M. Regarding current trading prices, CDXI is priced at $0.00, while PHGUF trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PHGUF's P/E ratio is -55.72. In terms of profitability, CDXI's ROE is +0.00%, compared to PHGUF's ROE of -0.06%. Regarding short-term risk, CDXI is more volatile compared to PHGUF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BPMUF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BPMUF has a market cap of 636.8M. Regarding current trading prices, CDXI is priced at $0.00, while BPMUF trades at $51.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BPMUF's P/E ratio is 7.32. In terms of profitability, CDXI's ROE is +0.00%, compared to BPMUF's ROE of -0.01%. Regarding short-term risk, CDXI is more volatile compared to BPMUF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs INRLF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, INRLF has a market cap of 552.7M. Regarding current trading prices, CDXI is priced at $0.00, while INRLF trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas INRLF's P/E ratio is -5.08. In terms of profitability, CDXI's ROE is +0.00%, compared to INRLF's ROE of -0.43%. Regarding short-term risk, CDXI is more volatile compared to INRLF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SOLTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SOLTF has a market cap of 533.3M. Regarding current trading prices, CDXI is priced at $0.00, while SOLTF trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SOLTF's P/E ratio is -32.78. In terms of profitability, CDXI's ROE is +0.00%, compared to SOLTF's ROE of -0.07%. Regarding short-term risk, CDXI is more volatile compared to SOLTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs IVEVF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, IVEVF has a market cap of 506.3M. Regarding current trading prices, CDXI is priced at $0.00, while IVEVF trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas IVEVF's P/E ratio is -1.05. In terms of profitability, CDXI's ROE is +0.00%, compared to IVEVF's ROE of +1.67%. Regarding short-term risk, CDXI is more volatile compared to IVEVF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CLTEF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CLTEF has a market cap of 504.7M. Regarding current trading prices, CDXI is priced at $0.00, while CLTEF trades at $7.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CLTEF's P/E ratio is -7.06. In terms of profitability, CDXI's ROE is +0.00%, compared to CLTEF's ROE of -0.43%. Regarding short-term risk, CDXI is more volatile compared to CLTEF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CKDXF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CKDXF has a market cap of 481.3M. Regarding current trading prices, CDXI is priced at $0.00, while CKDXF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CKDXF's P/E ratio is -1.26. In terms of profitability, CDXI's ROE is +0.00%, compared to CKDXF's ROE of +2.04%. Regarding short-term risk, CDXI is more volatile compared to CKDXF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs VBIZF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, VBIZF has a market cap of 472.2M. Regarding current trading prices, CDXI is priced at $0.00, while VBIZF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas VBIZF's P/E ratio is 22.70. In terms of profitability, CDXI's ROE is +0.00%, compared to VBIZF's ROE of -0.00%. Regarding short-term risk, CDXI is more volatile compared to VBIZF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs MDCLF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, MDCLF has a market cap of 463M. Regarding current trading prices, CDXI is priced at $0.00, while MDCLF trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas MDCLF's P/E ratio is -10.45. In terms of profitability, CDXI's ROE is +0.00%, compared to MDCLF's ROE of +0.60%. Regarding short-term risk, CDXI is more volatile compared to MDCLF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs AAVXF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, AAVXF has a market cap of 457.4M. Regarding current trading prices, CDXI is priced at $0.00, while AAVXF trades at $7.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas AAVXF's P/E ratio is -2.14. In terms of profitability, CDXI's ROE is +0.00%, compared to AAVXF's ROE of -2.11%. Regarding short-term risk, CDXI is more volatile compared to AAVXF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs RAONF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, RAONF has a market cap of 451.7M. Regarding current trading prices, CDXI is priced at $0.00, while RAONF trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas RAONF's P/E ratio is -43.33. In terms of profitability, CDXI's ROE is +0.00%, compared to RAONF's ROE of -0.71%. Regarding short-term risk, CDXI is more volatile compared to RAONF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BXPHF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BXPHF has a market cap of 451M. Regarding current trading prices, CDXI is priced at $0.00, while BXPHF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BXPHF's P/E ratio is -23.00. In terms of profitability, CDXI's ROE is +0.00%, compared to BXPHF's ROE of -0.18%. Regarding short-term risk, CDXI is more volatile compared to BXPHF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BOVNF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BOVNF has a market cap of 436.3M. Regarding current trading prices, CDXI is priced at $0.00, while BOVNF trades at $6.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BOVNF's P/E ratio is -12.05. In terms of profitability, CDXI's ROE is +0.00%, compared to BOVNF's ROE of -0.50%. Regarding short-term risk, CDXI is more volatile compared to BOVNF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CSPHF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CSPHF has a market cap of 435.6M. Regarding current trading prices, CDXI is priced at $0.00, while CSPHF trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CSPHF's P/E ratio is -32.10. In terms of profitability, CDXI's ROE is +0.00%, compared to CSPHF's ROE of -0.14%. Regarding short-term risk, CDXI is more volatile compared to CSPHF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs TBGNF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, TBGNF has a market cap of 433.7M. Regarding current trading prices, CDXI is priced at $0.00, while TBGNF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas TBGNF's P/E ratio is -0.25. In terms of profitability, CDXI's ROE is +0.00%, compared to TBGNF's ROE of N/A. Regarding short-term risk, CDXI is more volatile compared to TBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CYDY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CYDY has a market cap of 422.1M. Regarding current trading prices, CDXI is priced at $0.00, while CYDY trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CYDY's P/E ratio is -17.12. In terms of profitability, CDXI's ROE is +0.00%, compared to CYDY's ROE of +0.07%. Regarding short-term risk, CDXI is more volatile compared to CYDY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs HBMHF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, HBMHF has a market cap of 408M. Regarding current trading prices, CDXI is priced at $0.00, while HBMHF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas HBMHF's P/E ratio is 16.07. In terms of profitability, CDXI's ROE is +0.00%, compared to HBMHF's ROE of +0.02%. Regarding short-term risk, CDXI is more volatile compared to HBMHF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs GSGTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, GSGTF has a market cap of 403.2M. Regarding current trading prices, CDXI is priced at $0.00, while GSGTF trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas GSGTF's P/E ratio is -8.16. In terms of profitability, CDXI's ROE is +0.00%, compared to GSGTF's ROE of +0.78%. Regarding short-term risk, CDXI is more volatile compared to GSGTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PTCHF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PTCHF has a market cap of 396.3M. Regarding current trading prices, CDXI is priced at $0.00, while PTCHF trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PTCHF's P/E ratio is 7.86. In terms of profitability, CDXI's ROE is +0.00%, compared to PTCHF's ROE of -0.22%. Regarding short-term risk, CDXI is more volatile compared to PTCHF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs NWBO Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, NWBO has a market cap of 386.1M. Regarding current trading prices, CDXI is priced at $0.00, while NWBO trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas NWBO's P/E ratio is -4.46. In terms of profitability, CDXI's ROE is +0.00%, compared to NWBO's ROE of +1.13%. Regarding short-term risk, CDXI is more volatile compared to NWBO. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CLVLF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CLVLF has a market cap of 361.9M. Regarding current trading prices, CDXI is priced at $0.00, while CLVLF trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CLVLF's P/E ratio is 14.44. In terms of profitability, CDXI's ROE is +0.00%, compared to CLVLF's ROE of +0.19%. Regarding short-term risk, CDXI is more volatile compared to CLVLF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CLVLY Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CLVLY has a market cap of 348.9M. Regarding current trading prices, CDXI is priced at $0.00, while CLVLY trades at $6.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CLVLY's P/E ratio is 13.92. In terms of profitability, CDXI's ROE is +0.00%, compared to CLVLY's ROE of +0.19%. Regarding short-term risk, CDXI is more volatile compared to CLVLY. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs IDRSF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, IDRSF has a market cap of 337.2M. Regarding current trading prices, CDXI is priced at $0.00, while IDRSF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas IDRSF's P/E ratio is -0.91. In terms of profitability, CDXI's ROE is +0.00%, compared to IDRSF's ROE of +0.24%. Regarding short-term risk, CDXI is more volatile compared to IDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PRRUF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PRRUF has a market cap of 322.9M. Regarding current trading prices, CDXI is priced at $0.00, while PRRUF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PRRUF's P/E ratio is -11.05. In terms of profitability, CDXI's ROE is +0.00%, compared to PRRUF's ROE of -0.28%. Regarding short-term risk, CDXI is more volatile compared to PRRUF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs HLOSF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, HLOSF has a market cap of 321.6M. Regarding current trading prices, CDXI is priced at $0.00, while HLOSF trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas HLOSF's P/E ratio is -10.23. In terms of profitability, CDXI's ROE is +0.00%, compared to HLOSF's ROE of -1.30%. Regarding short-term risk, CDXI is more volatile compared to HLOSF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PBBIF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PBBIF has a market cap of 286.9M. Regarding current trading prices, CDXI is priced at $0.00, while PBBIF trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PBBIF's P/E ratio is 266.67. In terms of profitability, CDXI's ROE is +0.00%, compared to PBBIF's ROE of +0.01%. Regarding short-term risk, CDXI is more volatile compared to PBBIF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs GNFTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, GNFTF has a market cap of 276.3M. Regarding current trading prices, CDXI is priced at $0.00, while GNFTF trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas GNFTF's P/E ratio is 13.87. In terms of profitability, CDXI's ROE is +0.00%, compared to GNFTF's ROE of +0.27%. Regarding short-term risk, CDXI is more volatile compared to GNFTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs IPHYF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, IPHYF has a market cap of 267.3M. Regarding current trading prices, CDXI is priced at $0.00, while IPHYF trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas IPHYF's P/E ratio is -4.14. In terms of profitability, CDXI's ROE is +0.00%, compared to IPHYF's ROE of -1.81%. Regarding short-term risk, CDXI is more volatile compared to IPHYF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs TRGNF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, TRGNF has a market cap of 263.9M. Regarding current trading prices, CDXI is priced at $0.00, while TRGNF trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas TRGNF's P/E ratio is -6.06. In terms of profitability, CDXI's ROE is +0.00%, compared to TRGNF's ROE of -3.14%. Regarding short-term risk, CDXI is more volatile compared to TRGNF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs AVCTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, AVCTF has a market cap of 241M. Regarding current trading prices, CDXI is priced at $0.00, while AVCTF trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas AVCTF's P/E ratio is -5.19. In terms of profitability, CDXI's ROE is +0.00%, compared to AVCTF's ROE of -1.24%. Regarding short-term risk, CDXI is more volatile compared to AVCTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs OPORF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, OPORF has a market cap of 240.5M. Regarding current trading prices, CDXI is priced at $0.00, while OPORF trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas OPORF's P/E ratio is 17.50. In terms of profitability, CDXI's ROE is +0.00%, compared to OPORF's ROE of +0.42%. Regarding short-term risk, CDXI is more volatile compared to OPORF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ORYZF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ORYZF has a market cap of 234.9M. Regarding current trading prices, CDXI is priced at $0.00, while ORYZF trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ORYZF's P/E ratio is -43.29. In terms of profitability, CDXI's ROE is +0.00%, compared to ORYZF's ROE of -0.05%. Regarding short-term risk, CDXI is more volatile compared to ORYZF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs NWPHF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, NWPHF has a market cap of 231.2M. Regarding current trading prices, CDXI is priced at $0.00, while NWPHF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas NWPHF's P/E ratio is N/A. In terms of profitability, CDXI's ROE is +0.00%, compared to NWPHF's ROE of N/A. Regarding short-term risk, CDXI is more volatile compared to NWPHF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs HNSBF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, HNSBF has a market cap of 223.8M. Regarding current trading prices, CDXI is priced at $0.00, while HNSBF trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas HNSBF's P/E ratio is -2.58. In terms of profitability, CDXI's ROE is +0.00%, compared to HNSBF's ROE of +1.43%. Regarding short-term risk, CDXI is more volatile compared to HNSBF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BSEM Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BSEM has a market cap of 223M. Regarding current trading prices, CDXI is priced at $0.00, while BSEM trades at $13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BSEM's P/E ratio is -23.95. In terms of profitability, CDXI's ROE is +0.00%, compared to BSEM's ROE of +1.50%. Regarding short-term risk, CDXI is more volatile compared to BSEM. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SLNCF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SLNCF has a market cap of 212.5M. Regarding current trading prices, CDXI is priced at $0.00, while SLNCF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SLNCF's P/E ratio is -2.94. In terms of profitability, CDXI's ROE is +0.00%, compared to SLNCF's ROE of -0.87%. Regarding short-term risk, CDXI is more volatile compared to SLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SPHDF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SPHDF has a market cap of 211.9M. Regarding current trading prices, CDXI is priced at $0.00, while SPHDF trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SPHDF's P/E ratio is -3.65. In terms of profitability, CDXI's ROE is +0.00%, compared to SPHDF's ROE of +0.89%. Regarding short-term risk, CDXI is more volatile compared to SPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs FPHAF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, FPHAF has a market cap of 209.5M. Regarding current trading prices, CDXI is priced at $0.00, while FPHAF trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas FPHAF's P/E ratio is -7.50. In terms of profitability, CDXI's ROE is +0.00%, compared to FPHAF's ROE of N/A. Regarding short-term risk, CDXI is more volatile compared to FPHAF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs VSBC Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, VSBC has a market cap of 207M. Regarding current trading prices, CDXI is priced at $0.00, while VSBC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas VSBC's P/E ratio is N/A. In terms of profitability, CDXI's ROE is +0.00%, compared to VSBC's ROE of +0.00%. Regarding short-term risk, CDXI is more volatile compared to VSBC. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs FGHQF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, FGHQF has a market cap of 205.6M. Regarding current trading prices, CDXI is priced at $0.00, while FGHQF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas FGHQF's P/E ratio is 10.10. In terms of profitability, CDXI's ROE is +0.00%, compared to FGHQF's ROE of +0.00%. Regarding short-term risk, CDXI is more volatile compared to FGHQF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs NGENF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, NGENF has a market cap of 191.1M. Regarding current trading prices, CDXI is priced at $0.00, while NGENF trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas NGENF's P/E ratio is -9.09. In terms of profitability, CDXI's ROE is +0.00%, compared to NGENF's ROE of -2.23%. Regarding short-term risk, CDXI is more volatile compared to NGENF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs AMGXF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, AMGXF has a market cap of 190.7M. Regarding current trading prices, CDXI is priced at $0.00, while AMGXF trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas AMGXF's P/E ratio is -0.69. In terms of profitability, CDXI's ROE is +0.00%, compared to AMGXF's ROE of -0.24%. Regarding short-term risk, CDXI is more volatile compared to AMGXF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CMVLF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CMVLF has a market cap of 187.4M. Regarding current trading prices, CDXI is priced at $0.00, while CMVLF trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CMVLF's P/E ratio is -3.88. In terms of profitability, CDXI's ROE is +0.00%, compared to CMVLF's ROE of -0.30%. Regarding short-term risk, CDXI is more volatile compared to CMVLF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs SCNLF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, SCNLF has a market cap of 176M. Regarding current trading prices, CDXI is priced at $0.00, while SCNLF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas SCNLF's P/E ratio is -5.66. In terms of profitability, CDXI's ROE is +0.00%, compared to SCNLF's ROE of +2.45%. Regarding short-term risk, CDXI is more volatile compared to SCNLF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs RECEF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, RECEF has a market cap of 173M. Regarding current trading prices, CDXI is priced at $0.00, while RECEF trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas RECEF's P/E ratio is -10.00. In terms of profitability, CDXI's ROE is +0.00%, compared to RECEF's ROE of +2.26%. Regarding short-term risk, CDXI is more volatile compared to RECEF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs MLLCF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, MLLCF has a market cap of 155.6M. Regarding current trading prices, CDXI is priced at $0.00, while MLLCF trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas MLLCF's P/E ratio is -2.04. In terms of profitability, CDXI's ROE is +0.00%, compared to MLLCF's ROE of -0.36%. Regarding short-term risk, CDXI is more volatile compared to MLLCF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PBIGF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PBIGF has a market cap of 140.2M. Regarding current trading prices, CDXI is priced at $0.00, while PBIGF trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PBIGF's P/E ratio is -12.00. In terms of profitability, CDXI's ROE is +0.00%, compared to PBIGF's ROE of -2.16%. Regarding short-term risk, CDXI is more volatile compared to PBIGF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs CLABF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, CLABF has a market cap of 136.8M. Regarding current trading prices, CDXI is priced at $0.00, while CLABF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas CLABF's P/E ratio is -0.37. In terms of profitability, CDXI's ROE is +0.00%, compared to CLABF's ROE of -2.90%. Regarding short-term risk, CDXI is more volatile compared to CLABF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs BRIBF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, BRIBF has a market cap of 134.1M. Regarding current trading prices, CDXI is priced at $0.00, while BRIBF trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas BRIBF's P/E ratio is -1.83. In terms of profitability, CDXI's ROE is +0.00%, compared to BRIBF's ROE of -0.10%. Regarding short-term risk, CDXI is more volatile compared to BRIBF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs HOFBF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, HOFBF has a market cap of 130.4M. Regarding current trading prices, CDXI is priced at $0.00, while HOFBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas HOFBF's P/E ratio is -11.00. In terms of profitability, CDXI's ROE is +0.00%, compared to HOFBF's ROE of -1.07%. Regarding short-term risk, CDXI is more volatile compared to HOFBF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs AAPGV Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, AAPGV has a market cap of 127.3M. Regarding current trading prices, CDXI is priced at $0.00, while AAPGV trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas AAPGV's P/E ratio is N/A. In terms of profitability, CDXI's ROE is +0.00%, compared to AAPGV's ROE of N/A. Regarding short-term risk, CDXI is more volatile compared to AAPGV. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs PSTTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, PSTTF has a market cap of 117.5M. Regarding current trading prices, CDXI is priced at $0.00, while PSTTF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas PSTTF's P/E ratio is -29.00. In terms of profitability, CDXI's ROE is +0.00%, compared to PSTTF's ROE of N/A. Regarding short-term risk, CDXI is more volatile compared to PSTTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs EPRXF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, EPRXF has a market cap of 108.3M. Regarding current trading prices, CDXI is priced at $0.00, while EPRXF trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas EPRXF's P/E ratio is -2.69. In terms of profitability, CDXI's ROE is +0.00%, compared to EPRXF's ROE of -0.85%. Regarding short-term risk, CDXI is more volatile compared to EPRXF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs ADOIF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, ADOIF has a market cap of 103.7M. Regarding current trading prices, CDXI is priced at $0.00, while ADOIF trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas ADOIF's P/E ratio is -2.59. In terms of profitability, CDXI's ROE is +0.00%, compared to ADOIF's ROE of +6.08%. Regarding short-term risk, CDXI is more volatile compared to ADOIF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.
CDXI vs JWCTF Comparison
CDXI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDXI stands at 401. In comparison, JWCTF has a market cap of 101.3M. Regarding current trading prices, CDXI is priced at $0.00, while JWCTF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDXI currently has a P/E ratio of N/A, whereas JWCTF's P/E ratio is -1.25. In terms of profitability, CDXI's ROE is +0.00%, compared to JWCTF's ROE of -0.47%. Regarding short-term risk, CDXI is more volatile compared to JWCTF. This indicates potentially higher risk in terms of short-term price fluctuations for CDXI.